{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:37:32Z","timestamp":1761896252753},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T00:00:00Z","timestamp":1453161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T00:00:00Z","timestamp":1453161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/pcan.2015.66","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T12:04:35Z","timestamp":1453205075000},"page":"180-184","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study"],"prefix":"10.1038","volume":"19","author":[{"given":"D M","family":"Moreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G L","family":"Andriole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Castro-Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"BFpcan201566_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000328043","volume":"87","author":"P Pepe","year":"2011","unstructured":"Pepe P, Aragona F . Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int 2011; 87: 171\u2013174.","journal-title":"Urol Int"},{"key":"BFpcan201566_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11255-010-9825-5","volume":"43","author":"L Gui-Zhong","year":"2011","unstructured":"Gui-Zhong L, Libo M, Guanglin H, Jianwei W . The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol 2011; 43: 295\u2013301.","journal-title":"Int Urol Nephrol"},{"key":"BFpcan201566_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","volume":"60","author":"KS Sfanos","year":"2012","unstructured":"Sfanos KS, De Marzo AM . Prostate cancer and inflammation: the evidence. Histopathology 2012; 60: 199\u2013215.","journal-title":"Histopathology"},{"key":"BFpcan201566_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000020161","volume":"37","author":"PH Schatteman","year":"2000","unstructured":"Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E . Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37: 404\u2013412.","journal-title":"Eur Urol"},{"key":"BFpcan201566_CR5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/aje\/153.12.1152","volume":"153","author":"KA Rosenblatt","year":"2001","unstructured":"Rosenblatt KA, Wicklund KG, Stanford JL . Sexual factors and the risk of prostate cancer. Am J Epidemiol 2001; 153: 1152\u20131158.","journal-title":"Am J Epidemiol"},{"key":"BFpcan201566_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.juro.2006.04.075","volume":"176","author":"AV Sarma","year":"2006","unstructured":"Sarma AV, McLaughlin JC, Wallner LP, Dunn RL, Cooney KA, Schottenfeld D et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol 2006; 176: 1108\u20131113.","journal-title":"J Urol"},{"key":"BFpcan201566_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0090-4295(02)01637-0","volume":"60","author":"LK Dennis","year":"2002","unstructured":"Dennis LK, Lynch CF, Torner JC . Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78\u201383.","journal-title":"Urology"},{"key":"BFpcan201566_CR8","doi-asserted-by":"publisher","first-page":"e8736","DOI":"10.1371\/journal.pone.0008736","volume":"5","author":"I Cheng","year":"2010","unstructured":"Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One 2010; 5: e8736.","journal-title":"PLoS One"},{"key":"BFpcan201566_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/bju.12153","volume":"112","author":"TH Yli-Hemminki","year":"2013","unstructured":"Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TL et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013; 112: 735\u2013741.","journal-title":"BJU Int"},{"key":"BFpcan201566_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2008.20.3422","volume":"28","author":"PH Gann","year":"2010","unstructured":"Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E . Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 2010; 28: 1714\u20131720.","journal-title":"J Clin Oncol"},{"key":"BFpcan201566_CR11","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.juro.2010.12.058","volume":"185","author":"K Fujita","year":"2011","unstructured":"Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S . Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 2011; 185: 1722\u20131727.","journal-title":"J Urol"},{"key":"BFpcan201566_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/modpathol.2012.51","volume":"25","author":"ON Kryvenko","year":"2012","unstructured":"Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol 2012; 25: 1023\u20131032.","journal-title":"Mod Pathol"},{"key":"BFpcan201566_CR13","first-page":"4271","volume":"121","author":"DM Moreira","year":"2013","unstructured":"Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer 2013; 121: 4271.","journal-title":"Cancer"},{"key":"BFpcan201566_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000071839","volume":"71","author":"O Yaman","year":"2003","unstructured":"Yaman O, Gogus C, Tulunay O, Tokatli Z, Ozden E . Increased prostate-specific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int 2003; 71: 160\u2013164.","journal-title":"Urol Int"},{"key":"BFpcan201566_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192\u20131202.","journal-title":"N Engl J Med"},{"key":"BFpcan201566_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","volume":"44","author":"GL Andriole","year":"2003","unstructured":"Andriole GL, Kirby R . Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82\u201388.","journal-title":"Eur Urol"},{"key":"BFpcan201566_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.juro.2007.05.041","volume":"178","author":"JC Nickel","year":"2007","unstructured":"Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS . Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 2007; 178: 896\u2013900.","journal-title":"J Urol"},{"key":"BFpcan201566_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/pcan.2011.28","volume":"14","author":"C Wu","year":"2011","unstructured":"Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ . Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011; 14: 326\u2013331.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201566_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.urology.2007.06.1102","volume":"70","author":"E Kandirali","year":"2007","unstructured":"Kandirali E, Boran C, Serin E, Semercioz A, Metin A . Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70: 743\u2013747.","journal-title":"Urology"},{"key":"BFpcan201566_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00428-014-1554-1","volume":"464","author":"DM Berney","year":"2014","unstructured":"Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G et al. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch 2014; 464: 583\u2013587.","journal-title":"Virchows Arch"},{"key":"BFpcan201566_CR21","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.urology.2004.08.060","volume":"64","author":"LH Simardi","year":"2004","unstructured":"Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER . Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology 2004; 64: 1098\u20131101.","journal-title":"Urology"},{"key":"BFpcan201566_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0302-2838(02)00548-1","volume":"43","author":"F Di Silverio","year":"2003","unstructured":"Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 164\u2013175.","journal-title":"Eur Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201566","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:07:09Z","timestamp":1648674429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,19]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFpcan201566"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2015.66","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,19]]},"assertion":[{"value":"12 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RC-S is employed by GlaxoSmithKline. SJF has received a grant from GlaxoSmithKline. JCN has acted as a consultant for GlaxoSmithKline, Pfizer, Astellas and Lilly. He has provided expert testimony for GlaxoSmithKline and has received a grant from the company for the BPH Prostatitis Investigator-Initiated Study. GLA has received a grant from GlaxoSmithKline as well as a consulting fee for acting as chair of the REDUCE Steering Committee. He has also acted as a consultant for Bayer, Genomic Health, GlaxoSmithKline and Myriad Genetics. DMM declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}